TAVLESSE is the 1st AND ONLY TARGETED AGENT that helps prevent immune-mediated platelet destruction1-3 - NOW AVAILABLE IN THE UK

TAVLESSE (fostamatinib disodium hexahydrate) is a spleen tyrosine kinase (SYK) inhibitor indicated for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments.
 
Who is TAVLESSE for?
TAVLESSE is for adult patients with chronic ITP who have had an insufficient response to previous treatments
How is it administered?
TAVLESSE is an oral tablet taken twice daily with or without food
How does it work in the body?
TAVLESSE is a tyrosine kinase inhibitor that targets the spleen tyrosine kinase (SYK).1 The major active metabolite of TAVLESSE, R406, reduces the antibody-mediated destruction of platelets.

TAVLESSE differs from other treatments for chronic ITP by reducing SYK mediated platelet destruction,2 not stimulating increased platelet production4,5
When will more information be available?
We will continue to update this landing page as more information about Tavlesse becomes available.
Sign up to receive more information regarding Tavlesse®




Data Protection Information: Grifols UK Ltd, as data controller, will process your personal data to provide you with more information on the product. Legal basis: consent of the data subject. Recipients: Grifols group companies and other third parties. Data subject rights: to access, rectify and erase personal data, as well as other rights detailed in the additional information section. For additional information on how Grifols processes your personal data, please click here 

By signing up, I agree to my data being used as described in this form

THE TAVLESSE DIFFERENCE:
A unique mode of action targeted to limit platelet destruction
Fostamatinib inhibits SYK.1-3

Tavlesse (via its active metabolite) reduces antibody-mediated platelet destruction2
Click here to watch a video animation of the mode of action
Click Here to access the Prescribing Information
 
SYK = spleen tyrosine kinase; ITP = immune thrombocytopenia; PI3K = phosphatidylinositol-3-kinase; SLP76 = SH2-domain-containing leukocyte protein of 76 kDa; Rac = Rac family small GTPase
* R406 is the active matabolite of Tavlesse®.
1. Bussel JB, et al. Am J Hematol. 2018; 93:921-930. Doi: 10.1002/ajh.25125. 2. Tavlesse Summary of product characteristics. Grifols April, 2020. 3. Newland A, et al. Immunotherapy. 2018:10(1):9-25. 4. Nplate (romiplostim) Summary of product characteristics. Available at https:// www.medicines.org.uk/emc/product/567/smpc (last accessed August 2020) 5. Revolade (eltrombopag) Summary of product characteristics. Available at https://www.medicines.org.uk/emc/product/508/smpc (last accessed August 2020) 6. Shih A, et al. Press Med. 2014;43:e87-e95. 7. Nimmerjahn F, et al. Nature. 2008;8:34-47.
If you have questions regarding Tavlesse please contact: UKBioscience@grifols.com

If you have any medical queries please contact: Medinfo.uk@grifols.com
Grifols UK Ltd
Byron House, Cambridge Business Park, Cowley Rd,
Cambridge CB4 0WZ
www.grifols.com		 Privacy Policy Imprint Terms of Use Modern Slavery Statement Cookie Policy Cookie Settings

Tavlesse is a registered trademark of Grifols UK Ltd
© 2020 Grifols All rights reserved
UK-TVLS-2000003